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Gender-specific differences in 
PPARγ regulation of follicular 
helper T cell responses with 
estrogen
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Peroxisome proliferator-activated receptor gamma (PPARγ), a master regulator of adipocyte 
differentiation, has recently been connected with effector T cells, though its role is still not clear. Here, 
we investigated the roles of PPARγ in follicular helper T (TFH) cell responses regarding gender specificity. 
NP-OVA immunization in female but not male CD4-PPARγKO mice induced higher proportions of 
TFH cells and germinal center (GC) B cells following immunization than were seen in wild type mice. 
Treatment with the PPARγ agonist pioglitazone significantly reduced TFH cell responses in female mice 
while pioglitazone and estradiol (E2) co-treatment ameliorated TFH cells and GC responses in male 
mice. E2 treatment significantly enhanced PPARγ expression in male T cells, while T cell activation in 
the estrus but not in the diestrus stage of the menstrual cycle of females was inhibited by pioglitazone, 
suggesting that an estrogen-sufficient environment is important for PPARγ-mediated T cell regulation. 
These results demonstrate gender-based differences in sensitivities of PPARγ in TFH responses. 
These findings suggest that appropriate function of PPARγ is required in the regulation of female GC 
responses and that therapeutic strategies for autoimmune diseases using PPARγ agonists need to be 
tailored accordingly.
PPARγ is a transcription factor and a master regulator of adipocyte differentiation1–5. It is activated by ligands 
such as 15-deoxy-Δ12,14-prostagladin J2 (15d-PGJ2)6,7 and 13-hydroxyoctadecadienoic acid (13-HODE)8, which 
are derived from eicosanoids including prostaglandin D2 or fatty acid metabolites9. Thiazolidinediones (TZDs) 
such as pioglitazone, rosiglitazone, ciglitazone, and troglitazone are synthetic ligands for PPARγ10, and have been 
approved for use in the treatment of type 2 diabetes mellitus11. These ligands effectively inhibit NF-kB function to 
regulate inflammation and inflammatory diseases12.
PPARγ has been highlighted in T cell responses and autoimmune diseases and PPARγ ligand treatment has 
been shown to inhibit effector T cell functions in vitro and in vivo. Ciglitazone and 15d-PGJ2 inhibited T cell 
proliferation and IL-2 production13. We previously reported that pioglitazone inhibited human memory T cell 
responses in a model of arterial grafts14. Pioglitazone was also reported to selectively regulate Th17 cell responses 
to ameliorate experimental autoimmune encephalomyelitis (EAE)15. More recently, PPARγ -deficient Treg cells 
showed an impaired ability to migrate to visceral adipose tissue on a high-fat diet16 and failed to regulate effector 
T cell functions and development of colitis and GVHD17,18. In contrast, another study showed that PPARγ con-
tributed to the development of colitis in a lymphopenic environment19. Thus, there are still some controversies 
regarding the role of PPARγ in T cells.
Previously, we reported that female CD4-PPARγ KO mice have spontaneous autoimmune phenotypes with increased 
TFH cells and GC reactions20. Here, we observed that male CD4-PPARγ KO mice do not develop autoimmune pheno-
types and hypothesized that there are gender-based differences in PPARγ regulation of TFH cell responses. In this report, 
we demonstrate that an estrogen-sufficient environment promotes PPARγ activity to regulate TFH responses and we 
also suggest that PPARγ is more necessary in females to regulate effector T cell responses than it is in males.
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Results
Female CD4-PPARγKO but not male mice induce a higher proportion of TFH cells and GC B 
cells. Previously, we reported that female CD4-PPARγ KO mice spontaneously develop autoimmune pheno-
types with an increase in TFH cells with GC responses20. However, interestingly, 6-month to 1-year-old male 
CD4-PPARγ KO mice did not show spontaneous autoimmune phenotypes including the proportion of activated 
T cells (Supplementary Fig. S1a,b), autoantibodies in the serum (Supplementary Fig. S1c,d), and glomerulus 
inflammation (Supplementary Fig. S1e,f), which are typical indicators of systemic autoimmune diseases. In addi-
tion, there was no difference in the proportion of TFH cells in the spleen (Supplementary Fig. S1g,h). These results 
prompted us to consider the possibility of gender-based differences in phenotypic sensitivity of PPARγ deletion 
in T cells. To determine gender-based differences in TFH responses to antigen immunization in CD4-PPARγ KO 
mice, we first immunized six- to eight-week-old mice with NP-OVA (4-Hydroxy-3-nitrophenyl-ovalbumin) and 
analyzed TFH cells and GC responses in the draining lymph node seven days after the immunization (Fig. 1A). 
CXCR5 and Bcl-6 double-positive cells gated on CD4+CD44high were identified as TFH cells21–23. The proportion 
and the absolute cell number of TFH cells was significantly increased in female CD4-PPARγ KO mice compared 
with the wild-type littermate control group, while there was a significant decrease in TFH cells in the draining 
lymph node of male CD4-PPARγ KO mice (Fig. 1B,C, Supplementary Fig. S2a). In addition, female CD4-PPARγ 
KO mice displayed a significantly increased population and the cell number of of GL-7+CD95+ GC B cells, while 
male CD4-PPARγ KO mice showed a population of GC B cells smaller than that of the control group (Fig. 1D,E, 
Supplementary Fig. S2b). These data demonstrate that there are gender-specific effects of PPARγ deletion in T 
cells, and PPARγ is required to prevent TFH responses in female but not in male mice.
PPARγ agonist pioglitazone treatment reduces TFH responses in female but not in male mice. 
To determine whether PPARγ agonist pioglitazone treatment also shows gender-based differences in its effects 
on the induction of TFH cells and GC responses, six- to eight-week-old C57BL/6 mice were immunized with 
SRBC or NP-OVA, 10 mg/kg of pioglitazone was administered intra-peritoneally once a day from day 1 to day 
6, and TFH cells and GC responses were analyzed in the spleen or draining lymph node at day 7 (Fig. 2A). We 
observed that pioglitazone treatment significantly inhibited the proportion of TFH cells in the spleen compared to 
the DMSO-treated control group only in female mice, while no effect was observed in the males (Fig. 2B,C). The 
population of GC B cells was also significantly diminished by pioglitazone treatment in females, whereas it was 
not affected in male mice (Fig. 2D,E). Frozen spleen tissue was sectioned and stained to determine the T cell zone 
(anti-CD4-APC, blue), B cell zone (anti-IgD-PE, red), and GCs (PNA, green). The number of GCs was signifi-
cantly reduced in female mice, but not in males following pioglitazone treatment (Fig. 2F,G). These observations 
are consistent with those in a NP-OVA immunization model showing that pioglitazone treatment inhibited a 
proportion of TFH cells and GC cells of the draining lymph node only in female mice (Fig. 2H–K). These results 
collectively demonstrate that the stimulation of PPARγ via its ligand also has gender-based differences in effects 
in that it significantly inhibits TFH responses only in female mice but is not effective in males.
Pioglitazone and estradiol co-treatment in males reduces TFH responses. From the gender-specific 
results regarding TFH responses with PPARγ deletion in T cells or stimulation of PPARγ by its ligand follow-
ing immunization, we hypothesized that estrogen in the female might be important for this action of PPARγ . 
We first measured the basal PPARγ mRNA expression levels in male and female MACS-purified naïve T cells 
(CD4+CD62Lhigh) and also determined whether E2 treatment enhances PPARγ levels in male T cells. From the 
results, we found that PPARγ mRNA was expressed at significantly higher levels in female T cells than in males 
while male T cells had higher levels of PPARα and comparable expression of PPARδ (Fig. 3A). Interestingly, 5 nM 
E2 treatment of male T cells augmented PPARγ mRNA expression compared with DMSO-treated T cells, while 
no altered expression was found in E2-treated female T cells (Fig. 3B) suggesting that there is some positive feed-
back action of estrogen on PPARγ expression. To investigate the synergistic role of E2 and pioglitazone, six- to 
eight-week-old male C57BL/6 mice and CD4-PPARγ KO mice were immunized with NP-OVA and treated with 
either 60 μ g of E2 and/or 10 mg/kg of pioglitazone once a day from day 1 to day 6, then TFH cells and GC responses 
in the draining lymph node were analyzed seven days after immunization (Fig. 4A). In vivo administration of E2 
for six days results in significantly increased PPARγ mRNA expression in the spleen of male mice which is com-
parable level in estrus cycle of female mice (Supplementary Fig. S3). Only co-treatment with pioglitazone and E2, 
and not either treatment by itself, significantly inhibited the proportion of TFH cells in the lymph node compared 
to the other groups in male mice (Fig. 4B,C). The proportion of GC B cells was also significantly reduced by 
pioglitazone and E2 co-treatment (Fig. 4D,E). The lack of any effect of this co-treatment in CD4-PPARγ KO mice 
suggests that the co-treatment effect is dependent on PPARγ action. These results collectively suggest that E2 
enhances PPARγ sensitivity in male mice for the regulation of TFH responses.
Pioglitazone inhibits T cell activation in the estrus but not in the diestrus stage of the men-
strual cycle in females. Due to the dynamic estrogen cycle in females, we hypothesized that PPARγ sen-
sitivity in T cells might also differ during the menstrual cycle of female mice. We isolated splenocytes during 
the estrus and diestrus stages and then stimulated the cells with anti-CD3 and CD28 antibodies followed by 
pioglitazone treatment to determine if the differential PPARγ sensitivity depends on estrogen level (Fig. 5A). The 
levels of activation markers, CD25 and CD69, in CD4+ T cells were significantly reduced by pioglitazone treat-
ment in the cells only at estrus cycle but not at diestrus cycle (Fig. 5B,C). In addition, production of IFN-γ and 
IL-2 by activated splenocytes was also significantly decreased by pioglitazone only at the estrus stage of the cycle 
(Fig. 5D). These results seem to correlate with PPARγ expression level since the cells from the estrus stage have 
higher expression levels of PPARγ than cells from the diestrus stage (Fig. 5E). As consistent with previous results, 
pioglitazone treatment could not inhibit T cell activation in male splenocytes (Supplementary Fig. S4a–c). Taken 
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together, these results suggest that estrogen level has a positive correlation with PPARγ sensitivity to its ligand in 
females, thereby regulating T cell responses.
Discussion
PPARγ is a master regulator in adipocyte differentiation, which has important roles in lipid metabolism. PPARγ 
has been recently studied in T cells where it was shown to regulate Th17 cells to prevent autoimmunity and was 
also found to be necessary for regulatory T cell functions. Here, we demonstrate gender-specific actions of PPARγ 
regarding effector T cell functions, such as TFH responses, which are supported by estrogen.
Previously, it was reported that treatment with the PPARγ agonist pioglitazone augmented the incidence of 
hypoglycemia in diabetic women24 and that rosiglitazone showed a greater reduction of fasting plasma glucose 
Figure 1. Female CD4-PPARγKO but not male mice have higher proportions of TFH cells and GC B cells. 
(A) TFH cells were induced by immunization of six- to eight-week-old male and female littermate control and 
CD4-PPARγ KO mice with NP-OVA. Seven days after immunization, the proportion of TFH cells was analyzed by 
flow cytometry. (B,C) NP-OVA-immunized male and female littermate control and CD4-PPARγ KO mice were 
analyzed by staining with anti-Bcl-6 and anti-CXCR5 antibodies. Bcl-6 and CXCR5 double-positive cells gated 
on CD4+CD44high were identified as TFH cells and the % of Bcl-6+CXCR5+ TFH cells was represented as a bar 
graph. (D,E) Germinal center (GC) B cells in male and female littermate control and CD4-PPARγ KO mice were 
examined by staining with anti-GL-7 and anti-CD95 antibodies seven days after NP-OVA immunization and 
the % of GL-7+CD95+ GC B cells gated on B220-positive cells was indicated as a bar graph. The data represent 
means ± SEM (n = 4/group, three independent experiments). * P < 0.05, * * P < 0.01 by a two-tailed, unpaired 
Student’s t-test.
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(FPG) levels in women than in men25, suggesting that women have a greater sensitivity to treatment with PPARγ 
ligands. This gender-based difference in sensitivity would be correlated to the sex-dimorphic expression of 
PPARγ . Previously, a sex-specific action of PPARα was also reported when it was observed that male mice lack-
ing PPARα were more susceptible to EAE than were female mice and that PPARα expression level was higher in 
male T cells than in female T cells26. In addition, PPARα siRNA treatment affected only human male T cells by 
enhancing IFN-γ production, while there was no difference in IFN-γ expression in female T cells. PPARα ligand 
Figure 2. PPARγ ligand pioglitazone treatment reduces TFH responses in female but not in male mice. 
(A) Six- to eight-week-old male and female mice were immunized with SRBC or NP-OVA and were treated 
daily with pioglitazone (10 mg/kg) intra-peritoneally from day 1 to day 6. (B,C) The mice were sacrificed 
following SRBC immunization and the spleens were isolated and stained with anti-mouse CXCR5 and Bcl-6 
antibodies to analyze the proportion of TFH cells and the % of CXCR5+Bcl-6+-positive TFH cells was represented 
as a bar graph. (D,E) GL-7 and CD95 double-positive cells gated on B220-positive cells from the spleens 
from male and female mice were analyzed and the % of GL-7+CD95+ GC B cells was demonstrated as a bar 
graph (n = 3/group, three independent experiments). (F,G) Immunofluorescence analysis was performed to 
determine the number of GCs formed in spleens of SRBC-immunized male and female mice by staining with 
anti-PNA, -IgD, and -CD4 antibodies and the numbers of GCs were counted per spleen section. The average 
number of GCs per spleen section was determined (n = 9). (H,I) The inguinal lymph nodes were isolated from 
NP-OVA-immunized male and female mice. CXCR5+Bcl-6+-positive TFH cells were analyzed and displayed as a 
bar graph. (J,K) GL-7 and CD95 double-positive cells gated on B220-positive cells in the inguinal lymph nodes 
from male and female mice were analyzed and the % of GL-7+CD95+ GC B cells was represented as a bar graph. 
The data shown represent means ± SEM (n = 3 per group, two independent experiments). * P < 0.05, * * P < 0.01 
by a two-tailed, unpaired Student’s t-test.
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fenofibrate diminished IFN-γ production in males, but not in females27. Fenofibrate was also reported to reduce 
body weight and white adipose tissue (WAT) mass in high-fat-diet-fed male mice, but not in females28, suggesting 
that PPARα and PPARγ have gender-based specific sensitivities in their biological roles.
In general, women are more susceptible to autoimmune diseases compared to men29–31. Several factors includ-
ing hormones and the X-chromosome have been suggested to affect the higher prevalence rates of autoimmune 
diseases in females. We showed here that PPARγ expression is higher in T cells from female mice than in cells 
from males and that pioglitazone effects have a positive correlation with estrogen levels. Here we suggest that 
PPARγ controls TFH responses more sensitively in females with sufficient estrogen levels. This finding suggests 
that an abnormality in PPARγ activity in T cells might cause a more critical problem for maintaining homeostasis 
in females than in males. TFH cells are found in B cell follicles and interact with cognate B cells to promote iso-
type class switching, affinity maturation, and plasma cell differentiation to produce antibodies32,33. Therefore, TFH 
cells and GC reactions are important drivers of autoimmune disease by supporting autoantibody production34. 
Regulation of TFH cells is now considered to be an important target for treatment of autoimmune diseases35. We 
demonstrate that PPARγ plays a significant role in the regulation of TFH responses, especially in females, which 
would be important to prevent autoimmunity.
Decreased numbers of TFH cells in male CD4-PPARγ KO mice following NP-OVA immunization were observed 
in our experiments, raising the possibility that the discrepancy in PPARγ function acts as a negative regulator of 
effector T cell functions, although pioglitazone treatment has no effect in males. One recent paper reported that 
PPARγ is required for the development of autoimmunity in lymphopenic conditions due to increased apoptosis 
with reduced IL-7Rα expression of CD4-PPARγ KO T cells19, while there is a controversial result from previ-
ous studies showing that PPARγ is a negative regulator of T cell activation. It was reported that the transfer of 
PPARγ -deficient effector T cells into RAG-knockout mice showed a robust induction of colitis17. In addition, 
PPARγ deficiency in T cells showed increased Th17 and EAE disease pathogenesis and pioglitazone treatment 
selectively inhibited Th17 factors, suggesting a role for this drug in suppressing Th17 differentiation15. More 
recently, Treg-specific PPARγ deficiency showed an abnormality on Treg migration into adipose tissue in a 
high-fat diet animal model16. We hypothesize that this discrepancy could result from the different genders of the 
mice used. We determined that male PPARγ -deficient T cells have reduced levels of Bcl-2 and IL-7Rα expression, 
which are critical for T cell survival, while there is no difference in female CD4-PPARγ KO mice compared to 
their controls (Supplementary Fig. S5a,b). We also found that male PPARγ -deficient T cells are more apoptotic 
than wild-type controls in serum starvation conditions (Supplementary Fig. S5c,d). Therefore, PPARγ in males 
contributes to the survival of T cells by maintaining Bcl-2 and IL-7Rα expression while an estrogen-sufficient 
environment might compensate to sustain anti-apoptotic molecular expression in females36. Recently, role of 
IL-7Rα signaling in the regulation of TFH cells has been suggested that IL-7 suppressed the expression of Bcl-6 
and other TFH genes37. In addition, IL-7Rα -STAT5 axis is suggested as a negative regulator of TFH responses like 
IL-2-STAT538. However, another previous study regarding Foxo1 deletion in T cells with transgenic of IL-7Rα 
expression demonstrated that alteration of TFH responses are dependent on Foxo1 but not IL-7Rα 39. Thus, 
Figure 3. Estradiol treatment enhances the PPARγ expression. (A,B) Total RNA was isolated from male and 
female naïve T cells (CD4+CD62Lhigh) to determine the PPAR expression levels. Basal expression of PPARs in 
male and female naive T cells and PPARγ expression in 5 nM E2- or DMSO-treated male and female naïve T 
cells following TcR stimulation for 3 days were assessed using real-time PCR and were normalized to β -actin.  
* P < 0.05 by two-tailed, unpaired Student’s t-test. Values shown are means ± SEM (n = 3).
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possible reason for reduced induction of TFH cells without PPARγ in males need to be further investigated regard-
ing decreased IL-7Rα and Bcl-2 levels.
Synthetic ligands for PPARγ are used as anti-diabetes drugs for the treatment of type II diabetes mellitus40–44. 
Those ligands are also effective in the regulation of autoimmune diseases including colitis and EAE. Troglitazone 
and rosiglitazone treatment remarkably reduced disease severity in a mouse colitis model by inhibiting activa-
tion of NF-κ B45, while pioglitazone selectively inhibited Th17 cells to ameliorate the clinical features of EAE15. 
In addition to the synthetic ligands, various types of polyunsaturated fatty acid (PUFA) metabolites can serve as 
endogenous ligands for PPARγ to ameliorate inflammatory responses and autoimmune diseases. Previous studies 
have reported that PUFA metabolites, including eicosanoids and linoleic acid, modulated upregulation of PPARγ , 
resulting in reduced inflammation and IFN-γ production46,47. Animal models of inflammatory bowel diseases 
displayed significantly reduced colonic inflammation with PUFA feeding48 and reduced severity of EAE after 
PUFA supplementation49, suggesting that PPARγ has a potential role in the treatment of autoimmune diseases. 
Dietary intake of these metabolites could be an advantageous strategy, especially for females, to prevent autoim-
mune diseases by stimulating PPARγ to regulate sensitive TFH responses.
Estrogen is the predominant sexual hormone in females and several studies have demonstrated the anti- 
inflammatory50 and protective role of E2 in an EAE model51,52. Due to the protective role of estrogen in auto-
immune diseases, the incidence and severity of autoimmune diseases are worse in postmenopausal patients53, 
suggesting that the estrogen signal is essential to preventing autoimmunity. In our study, pioglitazone treatment 
inhibits activation of splenic T cells only when cells were collected during the estrus cycle and E2 treatment 
Figure 4. Pioglitazone and estradiol co-treatment in males reduces TFH responses. (A) Six- to eight-
week-old male CD4-PPARγ KO mice and the littermate control mice were immunized with NP-OVA and were 
treated daily with DMSO, pioglitazone (10 mg/kg), E2 (60 μ g), or pioglitazone (10 mg/kg) + E2 (60 μ g) intra-
peritoneally once a day from day 1 to day 6. (B,C) The mice were sacrificed on day 7 and inguinal lymph nodes 
were isolated and the cells were stained with anti-mouse CXCR5 and Bcl-6 antibodies to analyze the proportion 
of TFH cells and the % of CXCR5+Bcl-6+-positive TFH cells was indicated as a bar graph. (D,E) GL-7 and CD95 
double-positive cells gated on B220-positive cells from the lymph nodes were analyzed and the % of GL-
7+CD95+ GC B cells were represented as a bar graph. The data shown represent means ± SEM (n = 5/group, two 
independent experiments). One-way ANOVA was used for statistical analysis. * P < 0.05.
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increased the PPARγ expression level in male T cells, suggesting that estrogen and PPARγ have a positive corre-
lation in the regulation of T cell response. We did not observe any effect of E2 treatment alone on the regulation 
of TFH cells or GC responses, suggesting that E2 enhances PPARγ level to increase the sensitivity to its ligand. 
Therefore, estrogen hormonal imbalance in females might result in abnormal control of PPARγ action to regulate 
T cells, which could contribute to sensitive auto-antibody production via TFH responses. Molecular mechanisms 
of estrogen on PPARγ regulation and estrogen receptor deficiency in T cells will be further investigated regarding 
gender-specific regulatory mechanisms for TFH responses.
In conclusion, our findings suggest that there is gender-specific sensitivity of PPARγ in the regulation of TFH 
responses and that PPARγ -mediated regulation requires the estrogen signal in mice. Gender-based differences in 
therapeutic strategies using PPARγ agonists and combination treatments with estrogen should be considered for 
the treatment of autoimmune diseases.
Materials and Methods
Mice. B6.129-Ppargtm2Rev/J (PPARγ fl/fl) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). 
CD4-Cre+/− transgenic mice were crossed with PPARγ fl/fl mice to generate CD4-specific PPARγ -knockout mice 
(CD4-PPARγ KO). Mice were maintained at the Hanyang University mouse facilities under pathogen-free condi-
tions with ad libitum feeding. All animal protocols in this study were approved by the Animal Experimentation 
Ethics Committee of Hanyang University and experiments were performed according to the guidelines of the 
Institutional Animal Care and Use Committees (IACUC) of Hanyang University.
SRBC and NP-OVA immunization. Mice were immunized intra-peritoneally (i.p.) with sheep red blood 
cells (Innovative Research, Novi, MI, USA) diluted with DPBS at a 1:1 ratio and subcutaneously with 100 μ g of 
NP-OVA (Bioresearch Technologies, Novato, CA, USA). Seven days after immunization, mice were sacrificed and 
spleens and inguinal lymph nodes were isolated and analyzed by flow cytometry and confocal microscopy. For 
PPARγ agonist treatment, pioglitazone was purchased from Sigma and dissolved in DMSO. To assess the regula-
tory effect of pioglitazone on TFH cell differentiation in vivo, 10 mg/kg of pioglitazone was injected i.p. daily from 
day 1 to day 6 and the lymph nodes were isolated from the mice for further analysis.
Flow cytometry. Splenocytes, mesenteric, and inguinal lymph node cells were isolated and then stained 
with anti-mouse CD4-APC, CD8-PerCP-Cy5.5, CD44-PE, CD62L-FITC, GL-7-FITC, CD95-PE, and 
Figure 5. Pioglitazone inhibits T cell activation in the estrus but not in the diestrus stage of the menstrual 
cycle in females. (A) Menstrual cycle was monitored in six- to eight-week-old female C57BL/6 mice and 
splenocytes were isolated from the mice at estrus and diestrus stages. The cells were activated with anti-CD3 
and anti-CD28 antibodies for 24 h in the presence of DMSO or pioglitazone. (B,C) CD69 and CD25 expression 
gated on CD4-positive cells were analyzed with flow cytometry and the % of CD69- and CD25-positive cells 
were represented. (D) IFN-γ and IL-2 cytokine production levels following TcR stimulation were analyzed by 
ELISA using cultured supernatant. (E) Total RNA was isolated from female splenocytes from diestrus and estrus 
stages and the expression level of PPARs was analyzed by real-time PCR and normalized to β -actin. The data 
shown represent means ± SEM (n = 5/group). * P < 0.05, * * * P < 0.001 by a two-tailed, unpaired Student’s t-test.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:28495 | DOI: 10.1038/srep28495
B220-PerCP-Cy5.5 antibodies (eBioscience, San Diego, CA) for 15 min at 4 °C. For TFH differentiation analysis, 
the cells were stained with anti-mouse CXCR5-biotin for 30 min at 4 °C followed by anti-mouse CD44-FITC, 
CD4-PerCP-Cy5.5, and streptavidin-APC staining. After fixation and permeabilization using the Foxp3 Staining 
Kit (eBioscience), anti-mouse Bcl-6-PE was stained for 1 h at room temperature. Cells were examined using 
the FACSCanto II system (BD Bioscience, San Jose, CA, USA) and data were analyzed using Flow Jo software 
(Treestar, Ashland, OR, USA). In all cases, doublets (FSC-area versus FSC-height gating) were excluded.
RNA isolation and real-time PCR. RNA was isolated by a RNeasy mini kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer’s protocol. RNA yield and purity were determined by NanoDrop. Total 
RNA (500 ng) was used for cDNA synthesis in a 20-μ l reaction volume using qPCR RT Master Mix (Toyobo, 
Japan). Real-time PCR was performed using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). Actin 
was used as a control housekeeping gene. The following primer sequences were used (forward/reverse): 
PPARγ , 5′ -CTCCAAGAATACCAAAGTGCGA-3′ and 5′ -GCCTGATGCTTTATCCCCACA-3′ ; Actin, 
5′ -TGTCCCTGTATGCCTCTGGT-3′ and 5′ -CACGCACGATTTCCCTCTC-3′ .
Immunofluorescence. For GC formation analysis, the spleens from six- to eight-week-old sheep red blood 
cell (SRBC)-immunized mice were isolated 7 days after immunization and frozen in OCT compound. Tissues 
were sectioned to a 7-μ m thickness, fixed in acetone at − 20 °C, washed with PBS, and blocked with 0.1% BSA 
containing PBS for 30 min at room temperature. Tissues were stained with anti-PNA-FITC (Sigma-Aldrich, St. 
Louis, MO, USA), IgD-PE, and CD4-APC (eBioscience) antibodies diluted in blocking solution overnight at 4 °C. 
After three washes, tissues were incubated with ProLong Gold anti-fade reagent (Invitrogen, Life Technologies, 
Carlsbad, CA, USA) for 30 min at 4 °C and images were obtained using a Leica DM IRE2 confocal microscope.
ELISA. Cytokine production in activated T cells and Th1, Th2, and Th17 cells was measured by ELISA 
using mouse IL-4, IL-13, and IL-17 Ready-SET-Go kits (eBioscience) and IFN-γ and IL-2 ELISA Deluxe sets 
(BioLegend, San Diego, CA, USA) according to the manufacturers’ instructions. Anti-dsDNA antibody in mouse 
serum was quantified by ELISA (Alpha Diagnostic International Inc, San Antonio, TX, USA).
Statistical analysis. Data were analyzed statistically with the Student’s t-test and multiple comparisons were 
analyzed with one-way ANOVA using Prism5 (GraphPad, San Diego, CA, USA). P-values (P) less than 0.05 were 
considered statistically significant.
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